163 related articles for article (PubMed ID: 36057520)
1. [Radiation therapy and targeted therapies: Risks and opportunities].
Nicolas E; Lucia F
Cancer Radiother; 2022 Oct; 26(6-7):973-978. PubMed ID: 36057520
[TBL] [Abstract][Full Text] [Related]
2. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review.
Kroeze SG; Fritz C; Hoyer M; Lo SS; Ricardi U; Sahgal A; Stahel R; Stupp R; Guckenberger M
Cancer Treat Rev; 2017 Feb; 53():25-37. PubMed ID: 28056412
[TBL] [Abstract][Full Text] [Related]
3. Interaction between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence.
Debbi K; Grellier N; Loganadane G; Boukhobza C; Mahé M; Cherif MA; Rida H; Gligorov J; Belkacemi Y
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190205
[No Abstract] [Full Text] [Related]
4. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
5. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
6. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
[TBL] [Abstract][Full Text] [Related]
8. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
[TBL] [Abstract][Full Text] [Related]
9. [Combination of stereotactic irradiation and chemotherapy or targeted therapies: state of the art and preliminary recommendations].
Thariat J; Kirova Y; Milano G; Mornex F
Cancer Radiother; 2014; 18(4):270-9. PubMed ID: 25053603
[TBL] [Abstract][Full Text] [Related]
10. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA; Cicci TA; Auten JJ; Lowe DK
Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
[TBL] [Abstract][Full Text] [Related]
11. Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma.
Choi YS; Kwon H; You MH; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Endocr Relat Cancer; 2022 May; 29(6):307-319. PubMed ID: 35343921
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy and "new" drugs-new side effects?
Niyazi M; Maihoefer C; Krause M; Rödel C; Budach W; Belka C
Radiat Oncol; 2011 Dec; 6():177. PubMed ID: 22188921
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
Tartarone A; Lazzari C; Lerose R; Conteduca V; Improta G; Zupa A; Bulotta A; Aieta M; Gregorc V
Lung Cancer; 2013 Sep; 81(3):328-336. PubMed ID: 23809060
[TBL] [Abstract][Full Text] [Related]
14. HER2 aberrations in cancer: implications for therapy.
Yan M; Parker BA; Schwab R; Kurzrock R
Cancer Treat Rev; 2014 Jul; 40(6):770-80. PubMed ID: 24656976
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
[TBL] [Abstract][Full Text] [Related]
16. Is EGFR really a therapeutic target in head and neck cancers?
Agarwal V; Subash A; Nayar RC; Rao V
J Surg Oncol; 2019 May; 119(6):685-686. PubMed ID: 30701564
[TBL] [Abstract][Full Text] [Related]
17. Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed?
Wrona A
Cancer Radiother; 2019 Sep; 23(5):432-438. PubMed ID: 31331844
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms and Therapy for Cancer Metastasis to the Brain.
Franchino F; Rudà R; Soffietti R
Front Oncol; 2018; 8():161. PubMed ID: 29881714
[TBL] [Abstract][Full Text] [Related]
19. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Prahallad A; Sun C; Huang S; Di Nicolantonio F; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R
Nature; 2012 Jan; 483(7387):100-3. PubMed ID: 22281684
[TBL] [Abstract][Full Text] [Related]
20. Molecular subtyping of brain metastases and implications for therapy.
Renfrow JJ; Lesser GJ
Curr Treat Options Oncol; 2013 Dec; 14(4):514-27. PubMed ID: 23907440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
